C22orf39: A Potential Drug Target and Biomarker (G128977)

Target Name: C22orf39

NCBI ID: G128977

C22orf39

C22orf39: A Potential Drug Target and Biomarker

C22orf39 is a gene that encodes a protein known as C22orf39. The protein is composed of 224 amino acids and has a calculated molecular weight of 21.1 kDa. C22orf39 is located on chromosome 18 at position 686, which makes it a potential candidate for many diseases, including cancer.

The protein encoded by C22orf39 has several unique features that make it an attractive drug target. One of these features is its modular structure. C22orf39 is composed of a single transmembrane domain and a cytoplasmic tail, which allows it to be easily targeted by small molecules. Additionally, the protein has a unique farnesylation state, which is a hallmark of protein stability and may influence its stability and function.

Another potential mechanism by which C22orf39 may be involved in diseases is its role in cell signaling. C22orf39 has been shown to play a role in regulating cell signaling pathways, including the TGF-β pathway. This pathway is involved in many diseases, including cancer, and may be a potential target for drugs that can inhibit its activity.

C22orf39 has also been shown to be involved in the regulation of cell adhesion. This is an important process that is involved in many diseases, including cancer, and may be a potential target for drugs that can inhibit its activity.

In addition to its potential role in cell signaling and adhesion, C22orf39 has also been shown to play a role in the regulation of cell cycle progression. This is an important process that is involved in many diseases, including cancer, and may be a potential target for drugs that can inhibit its activity.

Overall, C22orf39 is a protein that has many unique features that make it an attractive drug target. Its modular structure, farnesylation state, and role in cell signaling, adhesion, and cycle progression make it a promising candidate for many diseases. Further research is needed to fully understand the role of C22orf39 in diseases and to develop effective treatments.

Protein Name: Chromosome 22 Open Reading Frame 39

The "C22orf39 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C22orf39 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets